IVIG Privigen denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits Privigen Quantities — and Why You Can Appeal

Privigen (immune globulin intravenous, 10%) is administered in weight-based doses at intervals determined by your diagnosis and clinical response. UnitedHealthcare applies quantity limits to Privigen authorizations — typically specifying a maximum amount per infusion cycle or authorization period. A quantity-limits denial means your order exceeded UHC's default threshold without additional clinical justification. These denials are highly appealable when your prescriber documents the individualized clinical basis for the quantity requested.

## Why This Denial Is Appealable

Quantity limits are administrative defaults calibrated to average patients. If your body weight, diagnosis severity, infusion schedule, or clinical response requires a different quantity than the default, that individualized rationale is grounds for an override. UHC cannot apply a blanket quantity cap when medical documentation supports a different amount. The FDA-approved prescribing information for Privigen specifies an approved dosing range for each indication — your prescriber's order should be traceable to that labeling.

## Federal Appeal Framework

• ERISA §503 (employer plans): Requires UHC to disclose the quantity-limit criteria and conduct a genuine individual review.
• ACA §2719 / State external review: Available after internal levels are exhausted. Act within approximately four months of your denial notice.
• Expedited review: Request it if your infusion is scheduled imminently or if a gap in therapy poses clinical risk — UHC's timeline for expedited review is significantly shorter than standard.

## Your Appeal Process

1. Request the denial letter and UHC's Privigen quantity-limit policy in writing. 2. Identify the specific limit applied and confirm the clinical basis for the quantity your prescriber ordered. 3. File a Level 1 internal appeal with your documentation package within the deadline on the denial notice. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis and indication: Specialist notes confirming your FDA-recognized indication for Privigen.
• Weight-based dosing calculation: Your prescriber's documented calculation showing why the quantity ordered is medically appropriate — this should reference the FDA-approved prescribing information for your indication's dosing range.
• Infusion schedule and frequency: The prescribed interval and clinical rationale, particularly if it differs from a standard protocol.
• Clinical-response records: Objective measures of your response (or inadequate response) to prior infusion quantities — trough levels, functional assessments, symptom documentation.
• Medical-necessity letter: Your specialist's explanation of why the requested quantity is medically necessary for your specific case, referencing the applicable guideline organization (e.g., relevant immunology or neurology society guidance) generically.

## Criteria-Mapping Strategy

Obtain UHC's published clinical policy and quantity-limit schedule for Privigen/IVIG. Map every limit criterion to your chart evidence in a structured table. If your quantity exceeds the default due to weight or clinical-response factors, your prescriber's letter must make that calculation explicit and tie it to the FDA-approved dosing guidance. A transparent, step-by-step justification is more persuasive than a general medical-necessity assertion.